<DOC>
	<DOCNO>NCT01797900</DOCNO>
	<brief_summary>The purpose study determine whether Intensity-modulated radiation therapy ( IMRT ) combine inductive concurrent chemotherapy intensive regimen ( cisplatin paclitaxel ) feasible effective current standard treatment high-risk locally advanced NPC patient .</brief_summary>
	<brief_title>The Role Induction Chemotherapy High-risk Locally Advanced Nasopharyngeal Carcinoma Era IMRT</brief_title>
	<detailed_description>Meta-analysis show chemotherapy combine conventional radiotherapy locally advance naso-pharyngeal carcinoma improve 5-year overall survival 6 % , beyond concurrent chemotherapy cisplatin benefit . However , Lin 's ( Lin JC , 2004 ) study , locally advanced NPC high risk factor benefit conventional concurrent chemoradiation . Failure pattern analysis reveal local distant failure account 50 % respectively . Large-scale data demonstrate IMRT , local control achieve 90 % . Previous study show inductive chemotherapy decrease distant metastasis . We need effective strong chemotherapy , still need testify concurrent chemotherapy combine inductive chemotherapy . A prospective trial would thus provide valuable information help physicians patient precisely identify feasibility effectiveness inductive + concurrent chemotherapy combine IMRT high-risk locally advanced NPC .</detailed_description>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>biopsyproved NPC N3 T4N2 multiple lymphnodes involve least one mass 4 cm maximal diameter accord 7th UICC Staging provide write informed consent Kps &gt; 70 dostant metastasis Life expectancy≥6 month Adequate renal function , define follow : Serum creatinine &lt; 2 x institutional upper limitof normal ( ULN ) within 2 week prior registration ; creatinine clearance rate ( CCr ) ≥ 50 ml/min within 2 week prior registration determine 24 hour collection estimate CockcroftGault formula : CCr male = [ ( 140 age ) x ( wt kg ) ] [ ( Serum Cr mg/dl ) x ( 72 ) ] CCr female = 0.85 x ( CCrmale ) The following assessment require within 2 week prior start registration : Na , K , Cl , glucose , Ca , Mg , albumin . Prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free minimum 3 year ; noninvasive cancer ( For example , carcinoma situ breast , oral cavity , cervix permissible ) permit even diagnose treat &lt; 3 year ago Prior radiotherapy region study cancer would result overlap radiation therapy field Severe , active comorbidity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>adjuvant</keyword>
	<keyword>inductive</keyword>
	<keyword>concurrent</keyword>
	<keyword>chemoradiotherapy</keyword>
	<keyword>high-risk</keyword>
	<keyword>locally advanced</keyword>
	<keyword>NPC</keyword>
</DOC>